Eli Lilly's Experimental Pill Shows Promise for Weight Loss and Blood Sugar Control
Eli Lilly’s orforglipron pill lowered blood sugar and aided weight loss in Type 2 diabetes patients during clinical trials, showing a potential new treatment avenue.
Subscribe to unlock this story
We really don't like cutting you off, but you've reached your monthly limit. At just $3/month or $30/year, subscriptions are how we keep this project going. Start your free 7-day trial today!
Get Started
While weight-loss jabs have soared in popularity, health officials believe that daily pill versions of the medicine could allow more people to control their weight and blood sugar levels.
New daily weight-loss pill shows success at clinical trial
The Guardian·3d·ReliableThis source consistently reports facts with minimal bias, demonstrating high-quality journalism and accuracy.Leans LeftThis outlet slightly leans left.
Orforglipron is taken orally, however, not as a weekly injection.
Lilly says daily pill can lower blood sugar and weight in people with Type 2 diabetes
NBC News·3d·ReliableThis source consistently reports facts with minimal bias, demonstrating high-quality journalism and accuracy.CenterThis outlet is balanced or reflects centrist views.
A daily pill would be easier to use and, because it would be cheaper to manufacture, could possibly lower patient costs, expert say.
CNN·3d·ReliableThis source consistently reports facts with minimal bias, demonstrating high-quality journalism and accuracy.Leans LeftThis outlet slightly leans left.
Companies like Lilly may only be able to push those boundaries so far, especially when it comes to regulatory decisions and economic pressures such as the tariffs the Trump Administration is planning to levy on imports.
How a New Weight-Loss Pill Could Transform Health
TIME Magazine·3d·ReliableThis source consistently reports facts with minimal bias, demonstrating high-quality journalism and accuracy.Leans LeftThis outlet slightly leans left.Orforglipron also targets GLP-1, but unlike hormone-mimicking peptides, which also include Novo Nordisk's injected Ozempic and Wegovy, it is a synthetic small molecule drug that can be taken orally.
Lilly Pill Leads to 8 Percent Weight Loss in Trial
Newsmax·3d·Mixed ReliableThis source has a mixed track record—sometimes accurate but also prone to bias, sensationalism, or incomplete reporting.RightThis outlet favors right-wing views.
Summary
Eli Lilly announced promising results from trials of its oral GLP-1 medication, orforglipron, which lowered A1C levels and resulted in significant weight loss among patients with Type 2 diabetes. Participants lost up to 8% of their body weight and over 65% maintained A1C under 6.5%. The company aims for FDA approval by the end of 2025 for diabetes treatment and hopes to offer a weight management option even sooner. Orforglipron's pill form may address patient hesitance toward injectable therapies, potentially increasing access to effective treatment for Type 2 diabetes and obesity.
Perspectives
Eli Lilly's experimental oral medication orforglipron has shown potential in reducing A1C levels and aiding weight loss in patients with Type 2 diabetes, comparable to existing injectable GLP-1 medications.
Orforglipron is the first oral drug of its kind to complete a Phase 3 trial, offering a potentially easier and less intimidating option for patients who may be hesitant to use injectables.
The drug has gained attention for its safety profile and effectiveness, as leading health experts anticipate it could play a significant role in treating obesity and diabetes.